Analysis of selected genetic variants in psoriasis susceptibility and response to treatment

INTRODUCTION: Aetiology of psoriasis is complex with risk factors involving both environmental triggers and genetic background. Although the best characterized genetic risk factor for psoriasis is HLA-C*06 allele, a number of other variants were associated with the disease. AIM: In the current paper...

Descripción completa

Detalles Bibliográficos
Autores principales: Malinowski, Damian, Białecka, Monika, Bojko, Piotr, Kiszkielis, Adriana, Droździk, Marek, Kurzawski, Mateusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704458/
https://www.ncbi.nlm.nih.gov/pubmed/36457676
http://dx.doi.org/10.5114/ada.2022.120885
Descripción
Sumario:INTRODUCTION: Aetiology of psoriasis is complex with risk factors involving both environmental triggers and genetic background. Although the best characterized genetic risk factor for psoriasis is HLA-C*06 allele, a number of other variants were associated with the disease. AIM: In the current paper we have conducted a confirmation study for SNPs located in 9 gene regions in a case-control analysis of 507 psoriatic patients and 396 controls from the Polish population. MATERIAL AND METHODS: Subsequently the impact of genetic variants on response to topical and NB-UVB therapy (reduction in the Psoriasis Area and Severity Index) was analysed. RESULTS: Significant differences in genotype and/or allelic frequency were observed for the following SNPs: rs33980500 (TRAF3IP2), rs582757 (TNFAIP3I), rs12188300 (IL12B), rs28998802 (NOS2), and rs2233278 (TNIP1). None of the genetic factors was associated with treatment outcome. CONCLUSIONS: Although the genetic variants have an impact on the disease risk, they are unlikely to be useful in personalization of topical therapy.

Ejemplares similares